See more : B90 Holdings PLC (B90.L) Income Statement Analysis – Financial Results
Complete financial analysis of Aarti Pharmalabs Limited (AARTIPHARM.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aarti Pharmalabs Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Newron Pharmaceuticals S.p.A. (NP5.DE) Income Statement Analysis – Financial Results
- Yuen Chang Stainless Steel Co., Ltd. (2069.TW) Income Statement Analysis – Financial Results
- Grand Prix International Public Company Limited (GPI.BK) Income Statement Analysis – Financial Results
- Yandal Resources Limited (YRL.AX) Income Statement Analysis – Financial Results
- Inventronics (Hangzhou), Inc. (300582.SZ) Income Statement Analysis – Financial Results
Aarti Pharmalabs Limited (AARTIPHARM.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aartipharmalabs.com
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited primarily engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in India and internationally. Its APIs and intermediates are used in various therapeutic areas, including anti-hypertensive, anti-asthmatic, anti-cancer, central nervous system (CNS) agents, skincare, decongestant, cardiovascular, anti-thalassemic, analgesic, anti-diabetic, and ophthalmologic medications. The company also develops new chemical entities (NCE), regulatory starting materials (RSM), basic starting materials, key starting materials (KSM), key building blocks, xanthine derivatives, and allied products. In addition, it provides contract development and manufacturing services for drug substance projects comprising NCEs, APIs, RSMs, and Intermediates for innovator pharmaceutical and biotech companies internationally. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 18.16B | 19.45B | 11.94B | 0.00 | 0.00 |
| Cost of Revenue | 14.25B | 11.70B | 10.01B | 0.00 | 0.00 |
| Gross Profit | 3.91B | 7.75B | 1.92B | 0.00 | 0.00 |
| Gross Profit Ratio | 21.53% | 39.87% | 16.11% | 0.00% | 0.00% |
| Research & Development | 83.70M | 139.61M | 58.16M | 0.00 | 0.00 |
| General & Administrative | 123.87M | 66.17M | 141.31K | 42.00K | 0.00 |
| Selling & Marketing | 679.71M | 588.14M | 261.36M | 0.00 | 0.00 |
| SG&A | 803.59M | 654.30M | 141.31K | 42.00K | 0.00 |
| Other Expenses | 49.00M | 23.20M | 15.90K | 0.00 | 0.00 |
| Operating Expenses | 7.01B | 4.96B | 785.66K | 45.96K | 186.75K |
| Cost & Expenses | 15.38B | 16.66B | 785.66K | 45.96K | 186.75K |
| Interest Income | 30.42M | 9.37M | 57.00K | 0.00 | 0.00 |
| Interest Expense | 172.15M | 210.50M | 1.62K | 0.00 | 0.00 |
| Depreciation & Amortization | 732.35M | 625.43M | 421.19M | 46.00K | 186.75K |
| EBITDA | 3.91B | 3.44B | 2.09B | 40.00 | 0.00 |
| EBITDA Ratio | 21.53% | 17.70% | -0.01% | 0.00% | 0.00% |
| Operating Income | 3.13B | 2.82B | -769.76K | -45.96K | -186.75K |
| Operating Income Ratio | 17.23% | 14.49% | -0.01% | 0.00% | 0.00% |
| Total Other Income/Expenses | -123.20M | -187.34M | -97.82M | 0.00 | 0.00 |
| Income Before Tax | 3.00B | 2.61B | -771.38K | -45.96K | -186.75K |
| Income Before Tax Ratio | 16.55% | 13.41% | -0.01% | 0.00% | 0.00% |
| Income Tax Expense | 835.90M | 672.90M | 331.29M | -46.00K | 0.00 |
| Net Income | 2.17B | 1.93B | -771.38K | -45.96K | -186.75K |
| Net Income Ratio | 11.95% | 9.95% | -0.01% | 0.00% | 0.00% |
| EPS | 23.93 | 21.35 | -0.01 | -0.18 | -0.75 |
| EPS Diluted | 23.93 | 21.35 | -0.01 | -0.18 | -0.75 |
| Weighted Avg Shares Out | 90.64M | 90.63M | 90.63M | 250.00K | 249.00K |
| Weighted Avg Shares Out (Dil) | 90.63M | 90.63M | 90.63M | 250.00K | 250.00K |
Source: https://incomestatements.info
Category: Stock Reports